The suspension granted until today's date was to give the...

The suspension granted until today's date was to give the company opportunity to clarify its financial position. Apart from budgeting to ensure that it doesn't breach its covenants, it seems fairly simple: there is merit in proceeding, or not. The company and the lenders have a Joint Steering committee who will make that decision and advise the board and the lenders.

Given that the company already advised that it would run out of money prior to this debacle they will have to work out where to raise or borrow funds to stay the distance. That will be difficult. A capital raise will be hard to imagine and further lending? Both need to be sanctioned by the FDA lender / investor